Log In
Print
BCIQ
Print
Print this Print this
 

HDM-SPIRE, ToleroMune house dust mite therapy

  Manage Alerts
Collapse Summary General Information
Company Circassia Pharmaceuticals plc
DescriptionT cell vaccine against house dust mites using ToleroMune T cell epitope desensitization technology
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationAllergy
Indication DetailsTreat house dust mite allergy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today